Literature DB >> 16235246

Proteasome inhibition induces selective motor neuron death in organotypic slice cultures.

Sachiko Tsuji1, Seiji Kikuchi, Kazuyoshi Shinpo, Jun Tashiro, Riichiro Kishimoto, Ichiro Yabe, Shoichi Yamagishi, Masayoshi Takeuchi, Hidenao Sasaki.   

Abstract

A dysfunctional ubiquitin-proteasome system recently has been proposed to play a role in the pathogenesis of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). We have shown previously that spinal motor neurons are more vulnerable to proteasome inhibition-induced neurotoxicity, using a dissociated culture system. To confirm this toxicity, we used organotypic slice cultures from rat neonatal spinal cords, which conserve the structure of the spinal cord in a horizontal plane, enabling us to identify motor neurons more accurately than in dissociated cultures. Furthermore, such easy identifications make it possible to follow up the course of the degeneration of motor neurons. When a specific proteasome inhibitor, lactacystin (5 microM), was applied to slice cultures, proteasome activity of a whole slice was suppressed below 30% of control. Motor neurons were selectively damaged, especially in neurites, with the increase of phosphorylated neurofilaments. They were eventually lost in a dose-dependent manner (1 microM, P < 0.05; 5 microM, P < 0.01). The low capacity of Ca(2+) buffering is believed to be one of the factors of selectivity for damaged motor neurons in ALS. In our system, negative staining of Ca(2+)-binding proteins supported this notion. An intracellular Ca(2+) chelator, BAPTA-AM (10 microM), exerted a significant protective effect when it was applied with lactacystin simultaneously (P < 0.01). We postulate that proteasome inhibition is an excellent model for studying the mechanisms underlying selective motor neuron death and searching for new therapeutic strategies in the treatment of ALS. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16235246     DOI: 10.1002/jnr.20665

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  7 in total

Review 1.  Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.

Authors:  Sareh Pandamooz; Mohammad Nabiuni; Jaleel Miyan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

2.  p53 and Cell Cycle Proteins Participate in Spinal Motor Neuron Cell Death in ALS.

Authors:  Srikanth Ranganathan; Robert Bowser
Journal:  Open Pathol J       Date:  2010-01-01

3.  Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis.

Authors:  Carsten W Lederer; Antonietta Torrisi; Maria Pantelidou; Niovi Santama; Sebastiano Cavallaro
Journal:  BMC Genomics       Date:  2007-01-23       Impact factor: 3.969

Review 4.  Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: a Link to Neurodegeneration.

Authors:  C Maurel; A Dangoumau; S Marouillat; C Brulard; A Chami; R Hergesheimer; P Corcia; H Blasco; C R Andres; P Vourc'h
Journal:  Mol Neurobiol       Date:  2018-01-10       Impact factor: 5.590

5.  Reduced proteasomal activity contributes to the accumulation of carbonylated proteins in chronic experimental autoimmune encephalomyelitis.

Authors:  Jianzheng Zheng; Oscar A Bizzozero
Journal:  J Neurochem       Date:  2010-11-19       Impact factor: 5.372

6.  Investigating Functional Regeneration in Organotypic Spinal Cord Co-cultures Grown on Multi-electrode Arrays.

Authors:  Martina Heidemann; Jürg Streit; Anne Tscherter
Journal:  J Vis Exp       Date:  2015-09-23       Impact factor: 1.355

7.  Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease.

Authors:  Manoj Kumar Jaiswal; Wolf-Dieter Zech; Miriam Goos; Christine Leutbecher; Alberto Ferri; Annette Zippelius; Maria Teresa Carrì; Roland Nau; Bernhard U Keller
Journal:  BMC Neurosci       Date:  2009-06-22       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.